pioneer 6 semaglutide Efficacy and safety of once-daily oral 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial Composite primary outcome in PIONEER

2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Study authors also noted the risk reductions were more pronounced in the cohorts with psoriasis than in those with obesity or diabetes without psoriasis, and that findings were consistent across all sensitivity analyses. Study authors concluded that GLP-1 receptor agonists should be considered for patients with psoriasis and comorbid obesity or diabetes.

The concern is that persistent upper-GI symptoms can occasionally mask a Tier 3 condition like acute cholecystitis, which GLP-1 drugs do modestly increase in risk [4]

(1999) 276:R15414

Dietary composition, particularly carbohydrates, fats, proteins, and fibre, significantly influences GLP-1 secretion from intestinal L-cells

The CCA for the remaining meta-analyses was 10.58%, indicating a high level of overlap